Complete Product Range
BiotechInnova represents the architect of modern trichology's final answer to the question: what is possible when we remove every constraint? Pharmaceutical-grade encapsulation. Clinical-standard protocols. No compromise.
The creator of Revita® and Spectral.DNC® — the formulations trusted by millions across 52 countries — has moved beyond the consumer model. BiotechInnova carries forward 20+ years of liposomal research to a new clinical standard, unbounded by mass-market distribution constraints.
Meet the Architect
BiotechInnova does not sell bottles. It administers a protocol. Each phase is engineered to create a continuous 24-hour biochemical activation cycle — preparing, treating, and sustaining the follicular environment at a depth conventional products cannot reach.
An efficacy-potentiated follicular synthesis cleanser at Clinical-Standard Grade IV Bio-Activity. Extends the anagen phase while preparing the scalp environment for deep-tissue potentiator uptake.
A high-density structural emulsion engineered for deep-tissue penetration. Wave Nanosome™ delivery ensures extended contact time at the follicular junction, catalyzing fiber integrity recovery within the dermal papilla.
The mid-day potentiator that sustains the biochemical activation window initiated in Phases I and II. Ensures the follicular environment remains primed for anagen retention during the critical mid-cycle period.
The stratum corneum blocks over 90% of topically applied compounds. Wave Nanosomes™ defeat this barrier through ultra-high frequency sonication — forming the most stable, smallest-particle true lipid bi-layer structures achievable in a pharmaceutical-grade process. Each molecule is optimized individually; there is no one-size-fits-all approach.
BiotechInnova materials are 100% performance-driven. Unlike competitors who use butters and waxes — which make it impossible to control loading or create a true bi-layer system in water — our Wave Nanosomes™ are method-optimized per molecule. If a competing encapsulation technology meets or exceeds our performance parameters in independent third-party testing, we refund all associated fees and costs in full.
If you are a current user of Revita® or Spectral.DNC®, you are using foundational technology developed by Daniel Khesin. BiotechInnova is the creator's direct answer to: what happens when we remove the limits?
You are not switching products. You are following the original innovator to the next threshold — to breakthroughs that consumer distribution models were never able to accommodate.
| Parameter | DS Laboratories | BiotechInnova |
|---|---|---|
| Activity Standard | Consumer Performance | Grade IV Bio-Activity |
| Delivery Vehicle | Original Nanosome Technology | Wave Nanosomes™ (next-gen) |
| Dermal Depth | Scalp surface penetration | Follicular junction saturation |
| Protocol Design | Shampoo + Conditioner | 3-Phase Sequential Cycle |
| Activation Window | Single-use contact time | Continuous 24-hour cycle |
| Bio-Active Count | Multi-ingredient blend | 12 Synergistic Bio-Actives |
| Language Standard | Marketing claims | Clinical-Standard Protocols |
Current users of DS Laboratories are invited into this new era. BiotechInnova is biotechnology designed by the man who built the industry — now optimized to redefine it.
View the ProtocolThe history of high-performance hair science is inextricably linked to the work of Daniel Khesin — the visionary founder and former CEO of DS Laboratories. As the primary architect behind the world's most recognized topical therapies, including the iconic Revita® and Spectral.DNC® lines, Khesin pioneered the integration of biotechnology into daily hair care. Under his leadership, these formulations reached millions of users globally, setting the industry benchmark for efficacy and liposomal delivery systems.
Having developed the entire current product catalog for DS Laboratories, Khesin recognized that the constraints of traditional consumer-marketing models were beginning to limit the potential of true biochemical breakthroughs. BiotechInnova represents his leap from performance-based hair care to Structural Bio-Synthesis — a singular mandate to push the efficacy threshold beyond conventional limits.
While his previous work established the global gold standard, BiotechInnova operates on the molecular frontier — utilizing pharmaceutical-grade protocols previously deemed too complex for mass-market distribution. This is biotechnology evolved: designed by the man who built the industry, now optimized to redefine it.
"BiotechInnova materials are entirely performance-driven — and this is what clients are paying for, 100% of the time."
Each BiotechInnova research program targets a major unmet need in skin science or transdermal delivery — conditions where current solutions consistently fail. Our 36-month R&D program targets preclinical validation and regulatory readiness across six therapeutic frontiers.
Liposome-stabilized delivery of mesenchymal stem cell exosomes into the dermis — enabling non-invasive treatment of scarring, burns, and aging without injections or transplantation.
Regenerative MedicineNano-vesicle encapsulation of JAK inhibitors and IL-17 blockers targeted to inflamed scalp regions — eliminating the need for systemic biologics and their associated costs and side effects.
Autoimmune / AlopeciaEncapsulated pregnenolone, testosterone, and citicoline in transdermal gels that bypass hepatic metabolism — enabling precise, sustained release without GI side effects or injections.
Transdermal SystemicVesicles engineered to respond to physiological cues — pH (acne), heat (inflammation), enzymes (eczema) — releasing actives only when and where the condition demands. Precision dermatology at scale.
Smart Drug DeliveryUltra-deformable transfersome liposomes capable of transporting vaccine components through the skin — painlessly, without syringes or cold-chain dependency. Applications in pediatrics and pandemic response.
Vaccine TechnologyEncapsulated anti-biofilm enzymes and quorum-sensing disruptors that defeat bacterial shielding — delivering antibiotics directly to pathogens in diabetic ulcers, resistant acne, and MRSA.
Anti-Microbial
